Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stock Holdings Raised by GAMMA Investing LLC

GAMMA Investing LLC raised its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 1,465.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,482 shares of the company's stock after buying an additional 31,343 shares during the period. GAMMA Investing LLC's holdings in Genmab A/S were worth $656,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Genmab A/S during the fourth quarter worth $2,463,000. AIMZ Investment Advisors LLC purchased a new position in Genmab A/S in the 4th quarter worth $3,525,000. Northern Trust Corp raised its stake in shares of Genmab A/S by 18.8% during the 4th quarter. Northern Trust Corp now owns 599,381 shares of the company's stock valued at $12,509,000 after buying an additional 94,858 shares during the last quarter. Sei Investments Co. raised its stake in shares of Genmab A/S by 55.2% during the 4th quarter. Sei Investments Co. now owns 57,702 shares of the company's stock valued at $1,205,000 after buying an additional 20,525 shares during the last quarter. Finally, LPL Financial LLC raised its stake in shares of Genmab A/S by 3.3% during the 4th quarter. LPL Financial LLC now owns 195,436 shares of the company's stock valued at $4,079,000 after buying an additional 6,288 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Performance

NASDAQ GMAB traded down $0.40 during trading hours on Friday, hitting $21.16. The company had a trading volume of 1,746,359 shares, compared to its average volume of 1,183,888. Genmab A/S Sponsored ADR has a 1-year low of $17.24 and a 1-year high of $28.56. The company has a market cap of $13.57 billion, a PE ratio of 12.02, a price-to-earnings-growth ratio of 6.98 and a beta of 0.96. The business has a 50 day moving average of $20.89 and a 200-day moving average of $20.74.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The firm had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. Sell-side analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on GMAB. Wall Street Zen lowered Genmab A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and issued a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Finally, Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.